These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 14986269)

  • 21. [In vitro resistance rates of Streptococcus pneumoniae and Haemophilus influenzae clinical isolates to the antibiotics used in therapy].
    Uncu H; Colakoğlu S; Turunç T; Demiroğlu YZ; Arslan H
    Mikrobiyol Bul; 2007 Jul; 41(3):441-6. PubMed ID: 17933256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Community-acquired pneumonia in Malaysian patients: addition of macrolide and the use of BTS "curb" index to assess severity.
    Loh LC
    Med J Malaysia; 2006 Mar; 61(1):128-30. PubMed ID: 16708753
    [No Abstract]   [Full Text] [Related]  

  • 23. Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia.
    Tessmer A; Welte T; Martus P; Schnoor M; Marre R; Suttorp N
    J Antimicrob Chemother; 2009 May; 63(5):1025-33. PubMed ID: 19293196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Penicillin resistance in pneumococcal pneumonia. Antibiotics with low resistance potential are effective and pose less risk.
    Cunha BA
    Postgrad Med; 2003 Jan; 113(1):42-4, 47-8, 52-4. PubMed ID: 12545592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of community-acquired pneumonia--treatment].
    Andersen LV; Brock B; Jakobsen P; Nielsen LP
    Ugeskr Laeger; 2008 Jan; 170(3):127-30. PubMed ID: 18208726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A step forward in the everyday management of adults with community acquired pneumonia.
    Woodhead M; Verheij TJ
    BMJ; 2005 Feb; 330(7489):460. PubMed ID: 15684021
    [No Abstract]   [Full Text] [Related]  

  • 27. [Community-acquired pneumonia--treatment perspectives in the physician's office].
    Ewig S
    MMW Fortschr Med; 2004 May; 146(21):43-5. PubMed ID: 15373084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High level of resistance to levofloxacin of Streptococcus pneumoniae following fluoroquinolone therapy.
    d'Escrivan T; Roussel-Delvallez M; Alfandari S; Guery B
    Infection; 2003 Oct; 31(5):366. PubMed ID: 14556066
    [No Abstract]   [Full Text] [Related]  

  • 29. [Initial empirical antibiotic treatment of community-acquired pneumonia].
    Frías J; Gomis M; Prieto J; Mensa J; Bouza E; García-Rodríguez JA; Torres A; Dorca J; Zalacaín R; García de Lomas J
    Rev Esp Quimioter; 1998 Sep; 11(3):255-61. PubMed ID: 9795313
    [No Abstract]   [Full Text] [Related]  

  • 30. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter?
    Peterson LR
    Clin Infect Dis; 2006 Jan; 42(2):224-33. PubMed ID: 16355333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
    Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibiotic treatment and the diagnosis of Streptococcus pneumoniae in lower respiratory tract infections in adults.
    Korsgaard J; Møller JK; Kilian M
    Int J Infect Dis; 2005 Sep; 9(5):274-9. PubMed ID: 16095941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.
    Echols RM; Tillotson GS; Song JX; Tosiello RL
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S166-75. PubMed ID: 18986284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN; Sader HS; Stilwell MG; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
    Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
    Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Doxycycline for nursing home acquired pneumonia (NHAP).
    Cunha BA
    Scand J Infect Dis; 2009; 41(1):77-8, author reply 76. PubMed ID: 18821134
    [No Abstract]   [Full Text] [Related]  

  • 39. Community-acquired bacteraemic pneumococcal pneumonia in adults: effect of diminished penicillin susceptibility on clinical outcome.
    Bonnard P; Lescure FX; Douadi Y; Schmit JL; Jounieaux V; Laurans G; Eb F; Ducroix JP
    J Infect; 2005 Jul; 51(1):69-76. PubMed ID: 15979494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.
    File TM; Monte SV; Schentag JJ; Paladino JA; Klugman KP; Lavin B; Yu VL; Singer ME; Adelman MH
    Int J Antimicrob Agents; 2009 Jan; 33(1):58-64. PubMed ID: 18835762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.